All articles by Phillip Broadwith – Page 4
-
PodcastThe Alchemy of Us by Ainissa Ramirez – Book club
Materials scientist Ainissa Ramirez’s new book uncovers the human side of world-changing inventions
-
OpinionHopes and fears for remdesivir
Available resources for testing coronavirus treatments need to be used wisely
-
-
ReviewIngredients: The Strange Chemistry of What We Put In Us and On Us
George Zaidan’s first book sets out to disentangle the confusing – and often conflicting – advice surrounding everyday items from processed food to sunscreen and beyond.
-
PodcastIngredients by George Zaidan – Book club
We discuss George Zaidan’s Ingredients, a book that promises to make chemistry more fun than Hogwarts
-
BusinessGetting ideas across
In a diverse industry like chemicals, we need to make sure we’re open to learning from unexpected angles.
-
OpinionTime for industry to show its humanity
Companies need to demonstrate community spirit in the face of the coronavirus pandemic
-
OpinionFossil industries promise net emissions reductions
Can the oil industry really curb its carbon output fast enough to impact climate targets?
-
OpinionStartup EQRx claims it can revolutionise drug discovery
If it can deliver reasonable drugs at knock-down prices, will providers be convinced?
-
BusinessDeadly explosion at ethylene oxide plant in Spain
Two employees killed and seven others injured at Iqoxe plant in Tarragona
-
BusinessTwo dead at US industrial tank cleaning site
Workers overcome by fumes in enclosed tanker truck
-
PodcastAntimony, Gold, and Jupiter’s Wolf by Peter Wothers – Book club
We talk about chemist Peter Wothers’ first popular science book that uncovers the surprising origins of the elements’ names
-
ReviewAntimony, Gold, and Jupiter’s Wolf: How the Elements Were Named
Accessible to chemists and non-chemists alike, this book traces the evolution of our understanding of the nature of matter itself
-
OpinionWhen should employees share profits from inventions?
Glucose monitor inventor wins £2m payout from Unilever after claiming his work provided ’outstanding benefit’
-
-
-
OpinionIs bankruptcy best for Purdue?
Many would prefer to see the Sackler family held personally liable, and the company wound down
-
OpinionWill Novartis's data manipulation damage relations with regulators?
Trust between the two has been compromised
-
OpinionAre new drugs better than existing ones?
Should companies be made to change the way they run clinical trials?
-
OpinionGet with the quantum program
Now is the time for industry to engage with the emerging world of quantum computers